FDA wins lawsuit over BuSpar listing

23 January 2001

A US district court has granted judgement in favor of the US Food andDrug Administration regarding the validity of its listing of a new patent relating to Bristol-Myers Squibb's BuSpar (buspirone HCl tablets) in the agency's Orange Book. The listing of the patent had been challenged by generics firms Watson Pharmaceuticals and Mylan (Marketletter December 11, 2000). Watson issued a statement after the verdict indicating that "this fight will continue." A separate lawsuit brought by Mylan is still pending.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight